Trump has a 'small personal financial interest' in hydroxycholorquine drugmaker. Allies have bigger stakes.


President Trump has been promoting the malaria and lupus drug hydroxychloroquine to treat COVID-19 "with all of the enthusiasm of a real estate developer," even as the medical experts on his coronavirus task force have repeatedly "warned against overselling a drug yet to be proved a safe remedy, particularly for heart patients," The New York Times reports. Some hospitals in Sweden stopped using hodroxycholoriquinine to treat the coronavirus due to adverse side effects, and the International Society of Antimicrobial Chemotherapy rejected a positive French study it had published on the drug, cited by Trump.
Dr. Anthony Fauci, the top U.S. infectious disease officials, has warned publicly and privately against promoting the drug absent studies showing its effectiveness, and "behind the scenes, career health officials have raised even stronger warnings about the risk to some Americans' heart health and other complications, but been warned not to publicly speak out and potentially contradict Trump," Politico reports. "Trump's focus on the drugs ... has increasingly warped his administration's response. Health officials have been told to prioritize the anti-malaria drugs over other projects that scientists believe have more potential to fight the outbreak." So...
"If hydroxychloroquine becomes an accepted treatment, several pharmaceutical companies stand to profit, including shareholders and senior executives with connections to the president," the Times reports. "Trump himself has a small personal financial interest in Sanofi, the French drugmaker that makes Plaquenil, the brand-name version of hydroxychloroquine." Other top Trump donors, allies, golf buddies, and Cabinet officials also have various ties to hydroxychlorquine.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
On the other hand, some hospitals in New York are using the drug to treat COVID-19, with mixed results. Senior administration officials tell Politico that Trump really believes hydroxychloroquine could end the COVID-19 pandemic. Trump has told associates Oracle founder Larry Ellison first pointed him to the drug, and TV personality Dr. Mehmet Oz, Rudy Giuliani, and trade adviser Peter Navarro have boosted his faith. "He thinks that it's the drug that's going to get everyone back to work," one Republican close to the White House told Politico, joking: "Do you have a supply?"
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
At home with the Clooneys: is arguing with your partner healthy?
The actor and his wife claim to have never argued during their 10-year marriage
By Richard Windsor, The Week UK
-
Quiz of The Week: 19 - 25 April
Have you been paying attention to The Week's news?
By The Week Staff
-
The Week Unwrapped: Why was Pope Francis controversial in Argentina?
Podcast Plus, could marriage increase your risk of dementia? And what is the true cost of that viral pistachio chocolate?
By The Week UK
-
Who would win in a China-US trade war?
Today's Big Question Tariff pain will be higher for China but Beijing is betting it can weather the storm
By Harriet Marsden, The Week UK
-
Lesotho: the tiny African nation in the crosshairs of Trump's tariff war
Under the Radar US president imposes 50% reciprocal levy on the impoverished state: the highest of his so-called 'Liberation Day' tariffs
By Harriet Marsden, The Week UK
-
What is the job market's future after Trump's tariffs?
Talking Points Economic analysts are split on what the tariffs could mean for employees
By Justin Klawans, The Week US
-
Is this the end of globalisation?
Today's Big Question American-led post-war order is 'finally starting to crumble' but that could bring about 'a more inclusive world'
By The Week UK
-
How could stock market slides affect you?
Today's Big Question Pensions, prices and jobs at risk as Donald Trump's 'Liberation Day' measures take hold
By The Week UK
-
Are free trade zones and alliances the answer to Trump's tariffs?
Today's Big Question Temptation is to retaliate with trade barriers, but most agree nations should focus on targeted trade pacts and strengthening cooperation
By Harriet Marsden, The Week UK
-
Trump tariffs: five scenarios for the world's economy
The Explainer A US recession? A trade war with China? How 'Liberation Day' could realign the globe
By Harriet Marsden, The Week UK
-
Markets notch worst quarter in years as new tariffs loom
Speed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
By Peter Weber, The Week US